Adipotide

Adipotide is a synthetic peptidomimetic studied for adipose-tissue vascular targeting and fat-mass reduction, but its development was discontinued because of safety concerns including renal toxicity.

Profile · 01

Overview

Adipotide is a peptidomimetic designed to target prohibitin-1 on blood vessels within white adipose tissue and deliver a pro-apoptotic signal to that tissue vasculature. It is not FDA-approved for any indication, and clinical development was discontinued after early human work because of safety concerns including reversible renal toxicity.

Most outcome support comes from rodent and primate studies showing fat-mass reduction. Because of the safety profile and limited human data, this page should be read as an educational research summary rather than a recommendation for use.

At a Glance

Goal
Study adipose-tissue vascular targeting and fat-mass reduction while emphasizing renal-risk awareness
Categories
Fat LossBody CompositionMetabolic SupportResearch Risk
Synergistic
AOD-9604 · 5-Amino-1MQ · CJC-1295 NO DAC + Ipamorelin
Profile · 02

Protocol

Conservative daily titration approach with emphasis on monitoring because of the compound risk profile.

Reconstitute
Add 3.0 mL bacteriostatic water to a 10 mg vial for about 3.33 mg/mL concentration
Typical daily range
250-1,000 mcg once daily
Start
250 mcg daily for Weeks 1-2
Target
Up to 1,000 mcg daily by Weeks 7-8 if well tolerated
Frequency
Once per day (subcutaneous)
Cycle Length
4-8 weeks
Timing
Any consistent time; rotate injection sites systematically
Route
Subcutaneous
Cycle
4-8 weeks on, 4-8 weeks off

Inject once daily subcutaneously and titrate slowly because the source material highlights renal toxicity as the main safety concern. Dosing is adapted from preclinical work and very limited early human observations. This is a higher-risk page than most peptide entries in the library.

Dose progression

Weeks 1-2
250 mcg (0.25 mg) · 8 units (0.08 mL)
Weeks 3-4
500 mcg (0.50 mg) · 15 units (0.15 mL)
Weeks 5-6
750 mcg (0.75 mg) · 23 units (0.23 mL)
Weeks 7-8
1,000 mcg (1.0 mg) · 30 units (0.30 mL)

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Science · 01

How Adipotide works.

Adipotide targets adipose-tissue vasculature by binding prohibitin-1 and delivering a pro-apoptotic sequence, leading to loss of blood supply in white adipose tissue. Preclinical rodent and primate studies reported meaningful weight and fat-mass reductions.

Clinical development did not progress because of safety issues, particularly reversible renal toxicity at higher exposures. That limitation is central to interpreting any educational discussion of the compound.

Science · 02

Effects

Observations from clinical or preclinical literature.

Preclinical studies reported notable reductions in fat mass and body weight
Mechanism is designed to target adipose vasculature rather than act through appetite regulation
Clinical development was discontinued because of safety concerns including renal toxicity
Kidney-related risk appears dose-dependent in the cited development history
Mild injection-site reactions such as redness or swelling may occur
Long-term human safety and efficacy remain unknown
Science · 03

Caution

Avoid in anyone with kidney disease, reduced renal function, or other major renal-risk factors
Not recommended during pregnancy or breastfeeding because safety data is insufficient
Use extreme caution because the development program was stopped for safety reasons
Qualified medical oversight is strongly recommended if this compound is discussed in a real-world context

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Lifestyle · 01

CoFactors

Adequate hydration
Supports renal function and is especially relevant given the safety concerns described for this compound.
Electrolytes
Support fluid balance and may help maintain overall tolerance during body-composition-focused protocols.
Omega-3 fatty acids
Support metabolic health and anti-inflammatory balance.
Protein intake
Helps preserve lean mass during fat-loss-focused interventions.
Lifestyle · 02

Life Factors

Complementary strategies for best outcomes.

Pair any body-composition protocol with a protein-forward, nutrient-dense diet
Use resistance training and aerobic activity to reinforce body-composition changes
Monitor hydration closely and avoid additional renal stressors where possible
Do not ignore early symptoms that could suggest renal intolerance
Lifestyle · 03

Metrics

Day-to-day metrics worth tracking through the protocol.

  1. Body composition - track weight, waist circumference, and body-fat trends
  2. Kidney-related symptoms - monitor urine changes, swelling, or other concerning signs
  3. Energy and general well-being - watch for systemic intolerance
  4. Injection-site reactions - note redness, swelling, or discomfort
Lifestyle · 04

Labs

Baseline and periodic bloodwork to monitor systemic health during the protocol.

BUN and creatinine
Primary renal monitoring markers for this compound.
eGFR
Tracks filtration capacity and renal safety trends.
CMP (Comprehensive Metabolic Panel)
Assesses broader liver and kidney function.
Urinalysis
Screens for proteinuria or other signs of renal stress.
CBC (Complete Blood Count)
General monitoring and baseline screening.
Calculators · 01

Supplies Calculator

Estimates assume the schedule defined for this peptide.

Length
Vial size
Bac. water
Syringe
Vials
0 × 10 mg each…
Syringes
0
Bac. water
0 mL
Swabs
02 per syringe
Calculators · 02

Dose Calculator

Dose Calculator

Vial
Bac. water
Syringe
Dose
Concentration
0mcg/mL
Volume per dose
0mL
…
Practice · 01

Preparation

Careful technique preserves potency. Solution should be clear — do not shake.

  1. Allow vial to reach room temperature for 15–20 minutes before reconstitution.
  2. Draw the chosen bacteriostatic water volume with a sterile syringe.
  3. Inject slowly down vial wall; avoid foaming.
  4. Gently swirl/roll until dissolved (do not shake).
  5. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  6. Use within 30 days; discard any unused solution after 30 days.
Practice · 02

Technique

General subcutaneous guidance from clinical best-practice resources.

Clean the vial stopper and injection site with alcohol and allow them to dry fully
Pinch a skinfold and insert the needle at 45-90 degrees into subcutaneous tissue
Do not aspirate for subcutaneous injections; inject slowly and steadily
Rotate sites across the abdomen, thighs, and upper arms
Discard used syringes immediately in a sharps container

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Practice · 03

Storage

Lyophilized
Store at room temp in dry, dark conditions; minimize moisture exposure.
Reconstituted
Refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles. Discard reconstituted vials after 30 days.

Notes

Allow vials to reach room temperature before opening to reduce condensation uptake.
Reference · 01

Notes

Use a new sterile insulin syringe for each injection and dispose of it safely
Rotate injection sites to reduce local irritation
Renal monitoring is the highest-priority safety consideration for this compound
This page reflects a discontinued development program with limited human evidence
PepTribe is an educational platform. This information is for research and learning purposes only and is not medical advice.
Reference · 02

References

  1. Science Translational Medicine
    Preclinical adipotide work in obese primates and adipose-tissue vascular targeting.
    https://stm.sciencemag.org/
  2. MD Anderson Cancer Center
    Summary coverage of adipotide-related preclinical findings.
    https://www.mdanderson.org/
  3. Arrowhead Pharmaceuticals
    Early clinical-development announcement for adipotide.
    https://www.arrowheadpharma.com/
  4. Cardiovascular Diabetology (PMC)
    Review context for adipose-tissue targeting strategies.
    https://pmc.ncbi.nlm.nih.gov/
  5. CDC
    Subcutaneous injection route guidance.
    https://www.cdc.gov/vaccines/hcp/admin/downloads/YCTS-VaxAdmin-Subcut-injection.pdf
  6. WHO (NCBI Bookshelf)
    Injection-safety guidance for subcutaneous administration.
    https://www.ncbi.nlm.nih.gov/books/NBK390474/
On this page